Goldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Neutral rating and a price target of $38.00.Analyst Navdeep ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE